Future directions in sarcoidosis research: Summary of an NHLBI Working Group

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 5, 2004, Pages 567-571

  Martin II, William J ^b   Iannuzzi, Michael C ^b   Gail, Dorothy B ^b   Peavy, Hannah H ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

Environmental; Genetics; Granuloma; Lung disease; National Institutes of Health (United States)

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; THALIDOMIDE;

CONFERENCE PAPER; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; ENVIRONMENTAL FACTOR; ETHNOLOGY; FAMILY HISTORY; HEALTH CARE FACILITY; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; LUNG SARCOIDOSIS; PRIORITY JOURNAL; RACE; RISK FACTOR; SIDE EFFECT;

BIOMEDICAL RESEARCH; HEALTH PLANNING GUIDELINES; HUMANS; SARCOIDOSIS; UNITED STATES;

EID: 4444291859     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200308-1073WS     Document Type: Conference Paper

References (43)

1. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis. Am J Respir Crit Care Med 1999;160:736-755.
2. Costabel U. Sarcoidosis: clinical update [review]. Eur Respir J Suppl 2001;32:56s-68s.
3. Newman LS, Rose CS, Maier LA. Sarcoidosis [review]. N Engl J Med 1997;336:1224-1234. [Published erratum appears in N Engl J Med 1997; 337:139.]
4. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-898.
5. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997;111:623-631.
6. Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 1997;14:154-158.
7. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs. population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002;121:32-39.
8. Hirsch JG, Nelson CT, Chase MW, Israel HL, Goldstein RA, Siltzbach LE. The Kveim test. N Engl J Med 1971;284:1326-1328.
9. Holter JF, Park HK, Sjoerdsma KW, Kataria YP. Nonviable autologous bronchoalveolar lavage cell preperations induce intradermal epithelioid granulomas in sarcoidosis patients. Am Rev Respir Dis 1992;145:864-871.
10. Teirstein AS. Kveim antigen: what does it tell us about causation of sarcoidosis? [review]. Semin Respir Infect 1998;13:206-211.
11. Relman DA. The search for unrecognized pathogens. Science 1999;284:1308-1310.
12. Fredericks DN, Relman DA. Infectious agents and the etiology of chronic idiopathic diseases. Curr Clin Top Infect Dis 1998;18:180-200.
13. Brown ST, Brett I, Almenoff PL, Lesser M, Terrin M, Terstein AS, ACESS Research Group. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003;123:413-417.
14. Weber G, Shendure J, Tanenbaum DM, Church GM, Meyerson M. Identification of foreign gene sequences by transcript filtering against the human genome. Nat Genet 2002;30:141-142.
15. Xu Y, Stange-Thomann N, Weber G, Bo R, Dodge S, David RG, Foley K, Beheshti J, Harris NL, Birren B, et al. Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics 2003;81:329-335.
16. Nikkari S, Lopez F, Lepp PW, Cieslak PR, Ladd-Wilson S, Passaro D, Danila R, Relman DA. Broad-range bacterial detection and the analysis of unexplained death and critical illness. Emerg Infect Dis 2002;8:188-194.
17. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, et al., ACCESS Research Group. Familial aggregation of sarcoidosis: a Case-Control Etiologic Study of Sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085-2091.
18. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5 year study in a health maintenance organization [review]. Am J Epidemiol 1997;145:234-241.
19. Iannuzzi MC, Maliarik M, Rybicki B. Genetic polymorphisms in lung disease: bandwagon or breakthrough? Respir Res 2002;3:15.
20. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993;262:242-244.
21. Foley PJ, McGrath DS, Puscinska E, Petrek M, Kolek V, Drabek J, Lympany PA, Pantelidis P, Welsh KI, Zielinski J, du Bois RM. HLA-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol 2001;25:272-277.
22. Tobin MJ. Tuberculosis, lung infections, interstitial lung disease, and socioeconomic issues in AJRCCM 2001 [review]. Am J Respir Crit Care Med 2002;165:631-641.
23. Schurmann M, Lympany PA, Reichel P, Muller-Myhsok B, Wurm K, Schlaak M, Muller-Quernheim J, du Bois RM, Schwinger E. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000;162:861-864.
24. Schurmann M, Reichel P, Muller-Myhsok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001;164:840-846.
25. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003;167:1225-1231.
26. Rybicki BA, Maliarik MJ, Poisson LM, Sheffer R, Chen KM, Major M, Chase GA, Iannuzzi MC. The major histocompatibility complex gene region and sarcoidosis in African Americans. Am J Respir Crit Care Med 2003;167:444-449.
27. Iannuzzi MC. Genetics of sarcoidosis. Monaldi Arch Chest Dis 1998;53:609-613.
28. Tobin MJ. Tuberculosis, lung infections, interstitial lung disease, and journalology in AJRCCM 2002 [review]. Am J Respir Crit Care Med 2003;167:345-355.
29. Hutyrova B, Pantelidis P, Drabek J, Zurkova M, Kolek V, Lenhart K, Welsh KI, Du Bois RM, Petrek M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;165:148-151.
30. Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JW, van den Bosch JM, Wells AU, du Bois RM, Welsh KI. Increased frequency of the uncommon tumor necrosis factor-857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002;165:1119-1124.
31. Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis [review]. Semin Respir Infect 1998;13:166-173.
32. Brignola C, Belloli C, Ardizzone S, Astegiano M, Cottone M, Trallori G, Italian Cooperative Study Group. The relationship between heritability and smoking habits in Crohn's disease. Am J Gastroenterol 2000;95:3171-3175.
33. Inhohara N, Ogura Y, Fontalba A, Guiterrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusomoto S, Hashimoto M, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003;278:5509-5512.
34. Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager H Jr, Teirstein AS, Rossman MD, Rand CS. Depression in sarcoidosis. Am J Respir Crit Care Med 2001;163:329-334.
35. Curtis JR, Borson S. Examining the link between sarcoidosis and depression. Am J Respir Crit Care Med 2001;163:306-308.
36. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-1307.
37. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-247.
38. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Early treatment of Stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121:24-31.
39. Ziegenhagen MW, Rothe E, Zissel G, Muller-Quernheim J. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistent sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-190.
40. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155:1665-1669.
41. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-74.
42. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002;122:227-232.
43. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR. Etanercept for the treatment of Stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-185.